
Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters. Harmony Biosciences earned $22.71 million, and sales totaled $91.21 million in Q4.